Statistics from Altmetric.com
Bevacizumab is a murine-anti-human monoclonal antibody directed against vascular endothelial growth factor-A, which disrupts endothelial cell survival mechanisms, and the recruitment and development of new tumour blood supply. Bevacizumab has been shown to prolong the duration of survival of patients with metastatic colorectal cancer when combined with chemotherapy.1 Owing to its antiangiogenic properties, bevacizumab is also known to alter the healing process and to increase the rate of surgical wound healing complications, either in patients who underwent …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.